| 產(chǎn)品名稱 |
20.3 [TAb 250] |
| 商品貨號(hào) |
B163632 |
| Organism |
Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Cell Type |
hybridoma:lymphocyte |
| Product Format |
frozen |
| Morphology |
lymphoblast |
| Culture Properties |
suspension |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Applications |
The hybridoma cell line named 20.3 produces monoclonal antibody TAb 250. The TAb 250 monoclonal antibody is specific for an extracellular epitope of the c-erbB-2 protein (gp185). |
| Derivation |
Spleen cells were fused with P3X63Ag8.653 mouse myeloma cells. |
| Genes Expressed |
immunoglobulin; monoclonal antibody; against human c-erb B2 protein |
| Cellular Products |
immunoglobulin; monoclonal antibody; against human c-erb B2 protein |
| Tumorigenic |
Yes |
| Effects |
Yes, in pristane primed BALB/c mice |
| Comments |
Animals were immunized with NIH3T3 cells transfected with the human c-erb B2 oncogene. Spleen cells were fused with P3X63Ag8.653 mouse myeloma cells. The hybridoma cell line named 20.3 produces monoclonal antibody TAb 250. The TAb 250 monoclonal antibody is specific for an extracellular epitope of the c-erbB-2 protein (gp185). It inhibits in a dose-dependent manner the in vitro proliferation of human breast tumor cell lines that overexpress c-erbB-2. A culture deposited with the ATCC as HB-10646 in January of 1991 was found to be contaminated with mycoplasma. Progeny were cured by a 21-day treatment with BM Cycline. The cured cell line is available as CRL-2655. The original patent deposit is available as HB-10646. |
| Complete Growth Medium |
The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 20%.
|
| Subculturing |
Medium Renewal: Every 2 to 3 days Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 2 X 10 exp5 viable cells/ml. Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml. |
| Cryopreservation |
culture medium 95%; DMSO, 5% |
| Culture Conditions |
Temperature: 37.0°C |
| Isotype |
IgG1; kappa light chain |
| Name of Depositor |
Berlex Laboratories, Inc. |
| Deposited As |
mouse (B cell); mouse (myeloma) |
| References |
Shawver LK, et al. Anti-neoplastic drugs in cancer therapy. US Patent 6,123,939 dated Sep 26 2000
Hancock MC, et al. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity. Cancer Res. 51: 4575-4580, 1991. PubMed: 1678683
|
